Corcept Therapeutics Incorporated
CORT
$57.08
$5.9211.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 769.10M | 761.41M | 741.17M | 716.08M | 685.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 769.10M | 761.41M | 741.17M | 716.08M | 685.45M |
| Cost of Revenue | 13.46M | 12.98M | 13.39M | 11.66M | 10.75M |
| Gross Profit | 755.64M | 748.43M | 727.78M | 704.42M | 674.70M |
| SG&A Expenses | 503.42M | 448.73M | 401.86M | 351.63M | 314.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 777.32M | 716.61M | 675.60M | 614.13M | 574.58M |
| Operating Income | -8.22M | 44.80M | 65.57M | 101.95M | 110.87M |
| Income Before Tax | 12.13M | 66.46M | 88.51M | 126.21M | 136.12M |
| Income Tax Expenses | -35.21M | -33.19M | -17.60M | -7.44M | 2.12M |
| Earnings from Continuing Operations | 47.34 | 99.65 | 106.11 | 133.66 | 133.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.34M | 99.65M | 106.11M | 133.66M | 133.99M |
| EBIT | -8.22M | 44.80M | 65.57M | 101.95M | 110.87M |
| EBITDA | -6.76M | 46.12M | 66.89M | 103.30M | 112.01M |
| EPS Basic | 0.45 | 0.94 | 1.01 | 1.27 | 1.28 |
| Normalized Basic EPS | 0.07 | 0.40 | 0.53 | 0.76 | 0.82 |
| EPS Diluted | 0.35 | 0.82 | 0.88 | 1.13 | 1.16 |
| Normalized Diluted EPS | 0.03 | 0.35 | 0.46 | 0.67 | 0.74 |
| Average Basic Shares Outstanding | 415.79M | 415.46M | 415.41M | 415.23M | 414.24M |
| Average Diluted Shares Outstanding | 464.21M | 479.60M | 478.20M | 472.49M | 463.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |